Department of General Surgery, Kunshan First People's Hospital Affiliated to Jiangsu University, Kunshan, Jiangsu, China.
Department of Urology, Kunshan Hospital of Traditional Chinese Medicine, Kunshan, Jiangsu, China.
Curr Probl Cancer. 2020 Oct;44(5):100559. doi: 10.1016/j.currproblcancer.2020.100559. Epub 2020 Feb 21.
The aim of this study was to evaluate the prognostic role of Forkhead box A1 (FOXA1) in breast cancer and determine the relationship between FOXA1 and zinc finger of the cerebellum 1 (ZIC1). BCIP, GEPIA, and Oncomine databases were used to detect expression of FOXA1 and assess prognostic roles of FOXA1 and ZIC1 in invasive breast tumors. A total of 113 female invasive breast cancer cases were collected to investigate FOXA1 and ZIC1 expression via immunohistochemistry. Twenty pairs of frozen-thawed tumors were used to select reliable indicators via western blotting and real-time quantitative polymerase chain reaction. In addition, Kaplan-Meier curves and Cox regression analysis were performed to analyze the overall survival (OS) and relapse-free survival. Multiple databases showed that FOXA1 expression was elevated in invasive breast cancer and negatively related to ZIC1. BCIP database also displayed a poor prognosis of high FOXA1 and low ZIC1. FOXA1 was positively associated with tumor size, grading, lymph node metastasis, and Tumor Node Metastasis (TNM) staging, while ZIC1 expression was negatively related to grading, lymph node metastasis, and TNM staging. In Kaplan-Meier and Cox regression analysis, FOXA1 negative group and ZIC1 positive group had better OS rate and recurrence-free survival rate. In addition, a joint evaluation showed that "FOXA1- ZIC1+" had the highest OS and relapse-free survival, but "FOXA1+ ZIC1-" had the lowest ones. FOXA1 was negatively related to ZIC1 in breast cancer and they had different roles in clinicopathology and prognosis. Combined examination of FOXA1 and ZIC1 could bring more benefit to breast cancer patients.
本研究旨在评估叉头框蛋白 A1（FOXA1）在乳腺癌中的预后作用，并确定 FOXA1 与小脑锌指蛋白 1（ZIC1）之间的关系。使用 BCIP、GEPIA 和 Oncomine 数据库检测 FOXA1 的表达，并评估 FOXA1 和 ZIC1 在浸润性乳腺癌肿瘤中的预后作用。共收集 113 例女性浸润性乳腺癌病例，通过免疫组织化学检测 FOXA1 和 ZIC1 的表达。利用 Western blot 和实时定量聚合酶链反应，从 20 对冻融肿瘤中筛选可靠指标。此外，通过 Kaplan-Meier 曲线和 Cox 回归分析，分析总生存期（OS）和无复发生存期。多个数据库显示，FOXA1 在浸润性乳腺癌中表达上调，与 ZIC1 呈负相关。BCIP 数据库还显示高 FOXA1 和低 ZIC1 预示预后不良。FOXA1 与肿瘤大小、分级、淋巴结转移和肿瘤淋巴结转移（TNM）分期呈正相关，而 ZIC1 表达与分级、淋巴结转移和 TNM 分期呈负相关。在 Kaplan-Meier 和 Cox 回归分析中，FOXA1 阴性组和 ZIC1 阳性组的 OS 率和无复发生存率更高。此外，联合评估显示“FOXA1-ZIC1+”的 OS 和无复发生存率最高，而“FOXA1+ZIC1-”的 OS 和无复发生存率最低。FOXA1 在乳腺癌中与 ZIC1 呈负相关，它们在临床病理和预后方面发挥不同的作用。联合检查 FOXA1 和 ZIC1 可为乳腺癌患者带来更多获益。
